Intelligent bio solutions expects to achieve 32.6% gross profit expansion and increased profitability on higher-margin sales

Gross profit expected to surge by 32.6% unaudited revenue of $0.61 million for fiscal q2 and $1.48 million for the six months ended december 31, 2024 higher-margin cartridge sales driving profitability and long-term growth expanding u.s. and international market presence with fda submission and strategic partnerships new york, feb. 06, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) (“inbs” or the “company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its preliminary unaudited selected financial results for the fiscal second quarter and six months ended december 31, 2024.  for the fiscal 2025 second quarter and six-month period, the company anticipates: unaudited revenue of approximately $0.61 million for the three months ended december 31, 2024.
INBS Ratings Summary
INBS Quant Ranking